ストックスクリーナーアプリを入手
0.6744
2.68%
-0.0186
アフターアワーズ：
.68
0.0056
+0.83%
Lexaria Bioscience Corp (LEXX) 最新ニュース
Lexaria Updates Progress on Human Study #7 - Investing News Network
Lexaria advances semaglutide study with ethics review submission - Investing.com
Lexaria advances semaglutide study with ethics review submission By Investing.com - Investing.com Australia
Lexaria targets mid-June start for 5-week oral semaglutide study - Stock Titan
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - Investing News Network
Lexaria’s new video series zeroes in on a $75B GLP-1 market - Stock Titan
Lexaria Extends Material Transfer Agreement with PharmaCO Through 2026 for GLP-1 Drug Delivery Technology Evaluation - MEXC
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Th - GuruFocus
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Through 2026 - GuruFocus
Lexaria extends pharma partnership to evaluate GLP-1 technology By Investing.com - Investing.com South Africa
Lexaria extends pharma partnership to evaluate GLP-1 technology - Investing.com
Lexaria's pharma license stays active as 3 GLP-1 studies continue - Stock Titan
Lexaria's Human GLP-1 Study #5 Begins Dosing - 富途牛牛
Fit to Work: GLP-1 and Metabolic Health in the M&A Sector - Investing News Network
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - The Facts
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - The Facts
Lexaria Bioscience (LEXX) Advances Research with New Animal Stud - GuruFocus
Lexaria's 18-arm test will compare pills and capsules for two GLP-1 drugs - Stock Titan
Lexaria Bioscience: Drug Delivery Platform Innovator with Multiple Mainstream Applications - Investing News Network
Lexaria Bioscience (LEXX) Highlights Growth in GLP-1 Oral Market - GuruFocus
Weight-loss pill hit 600,000 scripts in 2 months as oral market builds - Stock Titan
Lexaria Bioscience (LEXX) Stock Profit Outlook (Trend Weakens) 2026-04-20Entry Points - Cổng thông tin điện tử tỉnh Tây Ninh
Can Lexaria Bioscience (NASDAQ:LEXX) Afford To Invest In Growth? - Sahm
Is Lexaria Bioscience (LEXX) stock an investment worth exploring (Eye on Rally) 2026-04-18Volume Leaders - Cổng thông tin điện tử tỉnh Tây Ninh
Lexaria Bioscience Corp. (LEXXW) - Minichart
Lexaria Bioscience (LEXX) Initiates 2026 Animal Study for Enhanced Formulations - GuruFocus
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - Investing News Network
Lexaria Launches New GLP-1 Study to Expand Drug Delivery IP - TipRanks
Lexaria lines up rat study to test drug formulas for new patents - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely - Yahoo Finance
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2026 - marketscreener.com
Lexaria Bioscience Corp reports results for the quarter ended February 28Earnings Summary - TradingView
LEXARIA BIOSCIENCE ($LEXX) Releases Q2 2026 Earnings - Quiver Quantitative
Lexaria 10-Q: Revenue $0.02M, EPS $(0.13) for Six Months Ended Feb 28, 2026 - TradingView — Track All Markets
Lexaria Bioscience (NASDAQ: LEXX) revenue plunges as going concern risk emerges - Stock Titan
Lexaria Bioscience Corp.Warrant (NQ: LEXXW - FinancialContent
Lexaria Bioscience Corp expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Can Lexaria Bioscience (LEXX) Stock increase dividends | Price at $0.93, Up 2.22%Community Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):